海南海藥(000566.SZ):與愛康集團簽訂戰略合作框架協議
格隆匯5月15日丨海南海藥(000566.SZ)公佈,爲積極響應國家“一帶一路”倡議,深化區域經濟合作,推動海南自由貿易港建設,深化在醫藥健康領域的合作,海南海藥股份有限公司(簡稱“海南海藥”)與馬來西亞愛康國際集團(簡稱“愛康集團”)本着“優勢互補、資源共享、互利共贏”的原則,經友好協商,決定建立戰略合作關係並於近日簽訂戰略合作框架協議。協議的主要內容包括引進愛康集團高品質大健康類產品 ;推動海南海藥中藥產品進入馬來西亞市場;品牌共建與市場推廣等。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.